Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.45 |
| ▸ | HTR2C | P28335 | 5/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL231854 | 0.78 | HTR2A (0.51) | HTR2AHTR2CNOTUMSIGMAR1 | |
| SCHEMBL233436 | 0.78 | HTR2A (0.47) | HTR2AHTR2CNOTUMSIGMAR1KDM4E | |
| SCHEMBL8447299 | 0.77 | HTR2A (0.45) | HTR2AHTR2CNOTUMSIGMAR1EGLN2 | |
| SCHEMBL31244687 | 0.77 | PDE4B (0.36) | EGLN2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL8447696 | 0.73 | HTR2A (0.43) | HTR2AHTR2CNOTUMSIGMAR1 | |
| SCHEMBL13448722 | 0.72 | HTR2A (0.42) | HTR2AHTR2CNOTUMSIGMAR1 | |
| SCHEMBL8654307 | 0.72 | HTR2A (0.43) | HTR2AHTR2CNOTUMSIGMAR1 | |
| SCHEMBL8658423 | 0.72 | HTR2A (0.43) | HTR2AHTR2CNOTUMSIGMAR1 | |
| SCHEMBL18911621 | 0.70 | HTR2A (0.73) | HTR2AHTR2CNOTUMSIGMAR1HTR1A | |
| SCHEMBL13279281 | 0.70 | HTR2A (0.40) | HTR2AHTR2CNOTUMSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524958-B2 | Tricyclic compound as CRTH2 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-12-13 | — | — | US | disclosed |
| US-20210403466-A1 | TRICYCLIC COMPUND AS CRTH2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-12-30 | — | — | US | disclosed |
| EP-3489235-A1 | TRICYCLIC COMPOUND AS CRTH2 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403466-A1 | TRICYCLIC COMPUND AS CRTH2 INHIBITOR | NR3C2, CRHR2, CRHR1 | HTR2A 604/4885HTR2C 749/4885NOTUM 3876/4885 |
| US-11524958-B2 | Tricyclic compound as CRTH2 inhibitor | NR1H2, NR3C2, NR1H4 | HTR2A 772/4885HTR2C 1011/4885NOTUM 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.